Mizuho has recently initiated Terns Pharmaceuticals Inc (TERN) stock to Buy rating, as announced on June 22, 2023, according to Finviz. Earlier, on June 7, 2023, Jefferies had initiated the stock to Buy, setting a price target of $18. ROTH MKM also initiated Buy rating with a price target of $23. Additionally, BMO Capital Markets initiated Outperform rating on May 8, 2023, with a target price of $18. JMP Securities analysts, in their report published on February 14, 2023, also initiated Mkt Outperform rating and set a price target of $17 for Terns Pharmaceuticals Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Terns Pharmaceuticals Inc (TERN) Stock Trading Recap
On Monday, Terns Pharmaceuticals Inc (TERN) stock saw a decline, ending the day at $8.34 which represents a decrease of $-0.21 or -2.46% from the prior close of $8.55. The stock opened at $8.66 and touched a low of $8.2 during the day, reaching a high of $9. The volume of shares traded was 1.21 million falling short of the average volume of 1.96 million.
TERN Stock Performance and Moving Averages
In recent trading, Terns Pharmaceuticals Inc (TERN) stock price has shown some volatility, fluctuating -14.29% over the last five trades and 8.59% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 17.46%, and it has gained 21.75% in the previous three months. Currently, TERN is trading at -8.47%, 0.96%, and 20.61% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TERN, a Healthcare sector stock, is trading -26.84% below its 52-week high but remains 155.83% above its 52-week low. The Average True Range (ATR) (14 days) of 0.78 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Terns Pharmaceuticals Inc’s Profitability and Valuation Ratios
Terns Pharmaceuticals Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of 17.46%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Terns Pharmaceuticals Inc’s market capitalization stands at $704.23 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 2.68, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 29.95% of Terns Pharmaceuticals Inc (TERN)’s shares, while financial institutions hold 59.54%.
Notable insider trades include Vignola Mark J., Chief Financial Officer at Terns Pharmaceuticals Inc (TERN), who sold 10000 shares on Sep 10 ’24, at $11 each, totaling $0.11 million. On Sep 09 ’24, Quigley Jill M., Director, sold 17235 shares for $10 each, amounting to $0.17 million. Additionally, on Jul 15 ’24, GORDON CARL L sold 50976 shares at $10 each, generating $0.51 million.
